IONS

ACCE thesis

Ionis develops antisense oligonucleotide drugs that bind to specific RNA sequences to treat rare diseases, with a portfolio spanning neurological, cardiovascular, and metabolic disorders. The company's antisense platform creates a sustainable competitive moat through proprietary chemistry modifications and extensive IP protection, while partnerships with Biogen, Roche, and AstraZeneca validate the technology and provide non-dilutive funding. Eplontersen for hereditary transthyretin amyloidosis polyneuropathy represents the primary near-term catalyst, with FDA approval expected in Q4 2024 following positive Phase 3 data showing superior efficacy to Alnylam's patisiran. Despite burning $380 million annually, Ionis sits on $1.8 billion in cash and maintains one of biotech's deepest pipelines with 40+ programs, trading at just 4x peak sales estimates for eplontersen alone.

• severe
  Massive cash burn

  Free cash flow of -$808M indicates unsustainable burn rate threatening going concern.
• high
  Extreme leverage

  Debt-to-equity ratio of 531% creates significant financial risk and covenant concerns.
• high
  Heavy insider selling

  Insiders sold $7.9M with zero purchases, signaling potential lack of confidence.
• moderate
  High short interest

  Short interest at 13.1% suggests meaningful bearish sentiment among investors.

Snapshot